{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:00:24Z","timestamp":1785222024128,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to assess the efficacy and safety of integrating programmed death-1 (PD-1) inhibitors with chemoradiotherapy (CRT) in the treatment of locally advanced nasopharyngeal carcinoma (LA-NPC), explore the optimal sequencing of immunotherapy, and to compare the short-term efficacy of different combination regimens during the induction phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 512 LA-NPC patients (stage III-IVA, excluding T3N0). Among these patients, 256 received PD-1 inhibitors combined with CRT, and another 256 underwent CRT alone. The two groups were matched for T stage, N stage, overall tumor stage, sex, and age. We compared outcomes including progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional failure-free survival (LRFFS), overall survival (OS), and adverse events between the two groups. Further subgroup analyses examined the 3-year PFS rates according to the timing of PD-1 inhibitor administration (induction, concurrent, and maintenance immunotherapy, induction plus concurrent immunotherapy, and induction-phase immunotherapy). We also compared the short-term efficacy of PD-1 inhibitors combined with induction chemotherapy (IC) versus IC alone, and the efficacy variations associated with antiangiogenic or anti- epidermal growth factor receptor (EGFR) therapy, different PD-1 inhibitors, and chemotherapy protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The PD-1 inhibitor combined with CRT group showed significantly improved 3-, 4-, and 5-year rates of PFS, OS, and DMFS compared to the CRT group (3-year PFS: 90.6% vs. 82.6%, 4-year PFS: 89.3% vs. 77.3%, 5-year PFS: 89.3% vs. 76.1%; all\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u00a00.05). No notable difference was observed in LRFFS. Subgroup analyses revealed no significant variation in 3-year PFS rates among different PD-1 inhibitor administration schedules. Following IC, the PD-1 inhibitor plus IC cohort demonstrated higher complete response rates and objective response rates for primary nasopharyngeal lesions, cervical lymph nodes, and retropharyngeal lymph nodes than the IC cohort. The addition of antiangiogenic or anti-EGFR therapies further improved these response rates. The incidence of adverse events was comparable between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combining PD-1 inhibitors with CRT significantly improves PFS, DMFS and OS in LA-NPC patients, with a favorable safety profile. No significant differences in efficacy were found across different PD-1 inhibitors and chemotherapy regimens, suggesting flexibility in treatment selection based on clinical circumstances.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1876101","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:27:32Z","timestamp":1785220052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety analysis of PD-1 inhibitors combined with chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Lizhen","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]},{"name":"Department of Oncology, The Tenth Affiliated Hospital of Guangxi Medical University (The First People\u2019s Hospital of Qinzhou)","place":["Qinzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]},{"name":"Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases","place":["Nanning, Guangxi, China"]},{"name":"Key Laboratory of Early Prevention and Treatment for Regional High-Frequency Tumor (Guangxi Medical University), Ministry of Education","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibin","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Tenth Affiliated Hospital of Guangxi Medical University (The First People\u2019s Hospital of Qinzhou)","place":["Qinzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rensheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, Guangxi, China"]},{"name":"Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases","place":["Nanning, Guangxi, China"]},{"name":"Key Laboratory of Early Prevention and Treatment for Regional High-Frequency Tumor (Guangxi Medical University), Ministry of Education","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12967-023-04673-8","article-title":"Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect","volume":"21","author":"Siak","year":"2023","journal-title":"J Transl Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.tranon.2017.11.002","article-title":"Treatment outcomes of 257 patients with locoregionally advanced nasopharyngeal carcinoma treated with nimotuzumab plus intensity-modulated radiotherapy with or without chemotherapy: a single-institution experience","volume":"11","author":"Wang","year":"2017","journal-title":"Transl Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.34133\/research.0211","article-title":"Supramolecular biomaterials for cancer immunotherapy","volume":"6","author":"Liang","year":"2023","journal-title":"Res (Wash D C)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221096214","article-title":"Current status and advances of immunotherapy in nasopharyngeal carcinoma","volume":"14","author":"Xu","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70037","article-title":"Induction camrelizumab and modified TPF (Nab-paclitaxel, cisplatin, and S-1) in locoregionally advanced nasopharyngeal carcinoma","volume":"116","author":"Yu","year":"2025","journal-title":"Cancer Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00327","article-title":"Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30520","article-title":"Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a randomized phase 3 clinical trial","volume":"123","author":"Peng","year":"2016","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101625","article-title":"Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial","volume":"53","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00504-7","article-title":"Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081586","article-title":"Th2 cells are associated with tumor recurrence following radiation","volume":"16","author":"Abdelhakiem","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00507-2","article-title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial","volume":"25","author":"Mell","year":"2024","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-01569","article-title":"Chemoradiation \u00b1 atezolizumab in limited-stage small cell lung cancer: results of NRG Oncology\/Alliance LU005","volume":"44","author":"Higgins","year":"2026","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00405-019-05699-9","article-title":"Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases","volume":"277","author":"Qu","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0587","article-title":"Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy","volume":"5","author":"Xu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1146898","article-title":"Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.249","article-title":"The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation","volume":"28","author":"Shah","year":"2009","journal-title":"Oncogene"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.24562","article-title":"Epstein-Barr virus-encoded microRNAs as regulators in host immune responses","volume":"14","author":"Wang","year":"2018","journal-title":"Int J Biol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1415246","article-title":"Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10307","article-title":"Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study","volume":"25","author":"Ma","year":"2003","journal-title":"Head Neck"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0b013e3283330590","article-title":"Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities","volume":"20","author":"Modjtahedi","year":"2009","journal-title":"Anticancer Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251316094","article-title":"Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis","volume":"17","author":"Zhang","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010084","article-title":"Tumor angiogenesis and anti-angiogenic strategies for cancer treatment","volume":"9","author":"Teleanu","year":"2019","journal-title":"J Clin Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1186\/s12885-024-12708-6","article-title":"Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR\/ALK-negative, advanced or metastatic non-small cell lung cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1624286","article-title":"Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study","volume":"15","author":"Gao","year":"2025","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.859938","article-title":"Real-world data of different immune checkpoint inhibitors for non-small cell lung cancer in China","volume":"12","author":"Miao","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1876101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:27:33Z","timestamp":1785220053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1876101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1876101"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1876101","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1876101"}}